Open an account

Immunitybio

IBRX · NASDAQ

$8.77+$0.35 (+4.16%)TodayMarket closed ·
Prev close $8.42

About IBRX

ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.

Employees
691
Headquarters
San Diego, California
Listed
Jul 28, 2015
Sector
Health Care
Industry
Biotechnology
Website
immunitybio.com

IBRX key statistics

Market cap
8.92B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
16.47M
Volume
12.24M
Open price
$8.31
High today
$8.90
Low today
$8.11
52 Week high
$12.43
52 Week low
$1.95

Immunitybio (IBRX) at a glance

Immunitybio (IBRX) last traded at $8.77, with a market cap of 8.92B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.11 and $8.90. The current price is 8.1% above the day's low and 1.5% below its high.

Volume so far is 12.24M shares, below the average of 16.47M shares a day.

Over the past year Immunitybio has ranged from $1.95 to $12.43, and now sits 65% of the way up that range.

Immunitybio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.0918.

The average analyst price target is $13.01, 48.3% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $13.01
Low
$12.12
Now
$8.77
High
$15.75

IBRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 35.1% on average.

  1. Q3 FY24: reported -$0.12 per share against an estimate of -$0.1836
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.204
  3. Q1 FY25: reported -$0.15 per share against an estimate of -$0.1306
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.1122
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.1102
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0959
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.0714
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.0918

IBRX news

  • Vandana Singh

    ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

  • Press releaseBusiness Wire

    ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

  • Dylan Berman

    ImmunityBio Stock Climbs Thursday: What's Going On?

  • Press releaseBusiness Wire

    FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

  • Vandana Singh

    Why Is ImmunityBio Stock Gaining Wednesday?

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Press releaseBusiness Wire

    ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

  • Evette Mitkov

    ImmunityBio Stock Jumps: What's Going On?

Similar companies

Companies in the same industry as Immunitybio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.